The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - AstraZeneca; Chugai Pharma; Kyowa Hakko Kirin; Lilly Japan; Nippon Boehringer Ingelheim; Nippon Kayaku; Ono Pharmaceutical
Research Funding - MSD (Inst)

Phase II study of erlotinib in advanced non-small cell lung cancer patients with leptomeningeal metastasis.
 
Kaname Nosaki
No Relationships to Disclose
 
Yoshimasa Shiraishi
No Relationships to Disclose
 
Fumihiko Hirai
Honoraria - Chugai Pharma; Kyowa Hakko Kirin; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Novartis (Inst)
 
Taishi Harada
No Relationships to Disclose
 
Daisuke Himeji
No Relationships to Disclose
 
Takeshi Kitazaki
No Relationships to Disclose
 
Noriyuki Ebi
No Relationships to Disclose
 
Akinobu Hamada
Research Funding - AstraZeneca; Chugai Pharma; Shimadzu
 
Takeharu Yamanaka
No Relationships to Disclose
 
Mitsuhiro Takenoyama
Honoraria - AstraZeneca; Chugai Pharma; Kyowa Hakko Kirin; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Lilly Japan (Inst); Nippon Boehringer Ingelheim (Inst); Novartis (Inst); Ono Pharmaceutical (Inst)
 
Kenji Sugio
No Relationships to Disclose